Page last updated: 2024-10-28

ibuprofen and Lymph Node Metastasis

ibuprofen has been researched along with Lymph Node Metastasis in 2 studies

Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine

Research Excerpts

Excerpt	Relevance	Reference
"Ibuprofen may inhibit lung cancer progression."	2.73	Factors associated with human small aggressive non small cell lung cancer. ( Berg, CD; Church, TR; Freedman, MT; Hocking, WG; Hu, P; Kvale, PA; Oken, MM; Prorok, PC; Ragard, LR; Riley, TL; Tammemagi, CM, 2007)

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (50.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Tammemagi, CM	1
Freedman, MT	1
Church, TR	1
Oken, MM	1
Hocking, WG	1
Kvale, PA	1
Hu, P	1
Riley, TL	1
Ragard, LR	1
Prorok, PC	1
Berg, CD	1

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial[NCT00002540]				76,685 participants (Actual)	Interventional	1993-11-16	Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Death Rates From All Causes

Deaths from all causes were compared between the prostate cancer screening arm and the usual care arm. Rate is the number of deaths divided by person years of follow-up in the study. (NCT00002540)
Timeframe: Events through 13 years of follow-up or through December 31, 2009.

Intervention	Deaths per 10,000 PY (Number)
Control	166.6
Prostate Screening	160.5

Deaths From All Causes

Deaths from all causes were compared between the prostate cancer screening arm and the usual care arm. (NCT00002540)
Timeframe: Events through 13 years of follow-up or through December 31, 2009.

Intervention	Participants (Number)
Control	7089
Prostate Screening	6855

Prostate Cancer Death Rates

Prostate cancer deaths confirmed in participants by a death review committee if available, otherwise by death certificate. Rate is the number of deaths divided by person years of follow-up in the study. (NCT00002540)
Timeframe: Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years.

Intervention	Deaths per 10,000 PY (Number)
Control	3.4
Prostate Screening	3.7

Prostate Cancer Deaths

Prostate cancer deaths confirmed in participants by a death review committee if available, otherwise by death certificate. (NCT00002540)
Timeframe: Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years.

Intervention	Participants (Number)
Control	145
Prostate Screening	158

Prostate Cancer Incidence

Prostate cancer diagnoses confirmed by medical record abstraction. Incidence rate (cumulative) defined as prostate cancer diagnoses divided by person years at risk for prostate cancer. (NCT00002540)
Timeframe: Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years.

Intervention	Participants (Number)
Control	3815
Prostate Screening	4250

Prostate Cancer Incidence Rates

Intervention	Diagnoses per 10,000 PY (Number)
Control	97.1
Prostate Screening	108.4

Complications of Diagnostic Evaluation (DE) Following a Positive Screening Test

Number of positive screens with complications (NCT00002540)
Timeframe: One year from screening examination

Intervention	Positive screens w/ complications (Number)
	When DE Led to Prostate Cancer Diagnosis	When DE Did Not Lead to Prostate Cancer Diagnosis
Prostate Screening	901	124

T0 (Baseline) DRE Screening Results

Digital Rectal Examination (DRE) result. (NCT00002540)
Timeframe: T0 (at study entry)

Intervention	Participants (Number)
	Negative	Positive	Inadequate screen
Prostate Screening	30456	2481	1192

T0 (Baseline) PSA Screening Results

Prostate-Specific Antigen (PSA) result. (NCT00002540)
Timeframe: T0 (at study entry)

Intervention	Participants (Number)
	Negative (<=4 ng/mL)	Positive (> 4 ng/mL)	Inadequate screen
Prostate Screening	31507	2718	22

T1 DRE Screening Results

Digital Rectal Examination (DRE) result. (NCT00002540)
Timeframe: T1 (one year after entry)

Intervention	Participants (Number)
	Negative	Positive	Inadequate screen
Prostate Screening	29311	2237	900

T1 PSA Screening Results

Prostate-Specific Antigen (PSA) result. (NCT00002540)
Timeframe: T1 (one year after entry)

Intervention	Participants (Number)
	Negative (<=4 ng/mL)	Positive (> 4 ng/mL)	Inadequate screen
Prostate Screening	30159	2502	27

T2 DRE Screening Results

Digital Rectal Examination (DRE) results (NCT00002540)
Timeframe: T2 (two years after entry)

Intervention	Participants (Number)
	Negative	Positive	Inadequate screen
Prostate Screening	28391	2327	733

T2 PSA Screening Results

Prostate-Specific Antigen (PSA) result. (NCT00002540)
Timeframe: T2 (two years after entry)

Intervention	Participants (Number)
	Negative	Positive (> 4 ng/mL)	Inadequate screen
Prostate Screening	29063	2593	35

T3 DRE Screening Results

Digital Rectal examination (DRE) result (NCT00002540)
Timeframe: T3 (three years after entry)

Intervention	Participants (Number)
	Negative	Positive	Inadequate screen
Prostate Screening	27179	2317	748

T3 PSA Screening Results

Prostate-Specific Antigen (PSA) result (NCT00002540)
Timeframe: T3 (three years after entry)

Intervention	Participants (Number)
	Negative (<=4 ng/mL)	Positive (> 4 ng/mL)	Inadequate screen
Prostate Screening	27814	2676	43

T4 PSA Screening Result

Prostate-Specific Antigen (PSA) result (NCT00002540)
Timeframe: T4 (four years after entry)

Intervention	Participants (Number)
	Negative (<=4 ng/mL)	Positive (> 4 ng/mL)	Inadequate screen
Prostate Screening	20362	1796	12

T5 PSA Screening Results

Prostate-Specific Antigen (PSA) result. (NCT00002540)
Timeframe: T5 (five years after entry)

Intervention	Participants (Number)
	Negative (<=4 ng/mL)	Positive (> 4 ng/mL)	Inadequate screen
Prostate Screening	23560	2377	14

Trials

1 trial available for ibuprofen and Lymph Node Metastasis

Article	Year
Factors associated with human small aggressive non small cell lung cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2007, Volume: 16, Issue:10 Topics: Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma, Non-Small-Cell Lung; C	2007

Other Studies

1 other study available for ibuprofen and Lymph Node Metastasis

Article	Year
Regular NSAID use appears to reduce breast cancer severity. Oncology (Williston Park, N.Y.), 1996, Volume: 10, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Breast Neoplasms; Chemoprevention; Female; Humans; Ibuprofe	1996